BlackRock’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-39,825
| Closed | -$154K | – | 5476 |
|
|
2024
Q3 | $154K | Sell |
39,825
-1,279
| -3% | -$3.54K | ﹤0.01% | 4581 |
|
|
2024
Q2 | $95.4K | Hold |
41,104
| – | – | ﹤0.01% | 4715 |
|
|
2024
Q1 | $116K | Sell |
41,104
-2,356
| -5% | -$6.98K | ﹤0.01% | 4695 |
|
|
2023
Q4 | $138K | Hold |
43,460
| – | – | ﹤0.01% | 4731 |
|
|
2023
Q3 | $143K | Sell |
43,460
-3,320
| -7% | -$10.3K | ﹤0.01% | 4760 |
|
|
2023
Q2 | $154K | Sell |
46,780
-10,870
| -19% | -$38.4K | ﹤0.01% | 4801 |
|
|
2023
Q1 | $191K | Buy |
57,650
+462
| +0.8% | +$1.62K | ﹤0.01% | 4789 |
|
|
2022
Q4 | $206K | Buy |
57,188
+71
| +0.1% | +$464 | ﹤0.01% | 4848 |
|
|
2022
Q3 | $506K | Sell |
57,117
-385
| -0.7% | -$3.2K | ﹤0.01% | 4729 |
|
|
2022
Q2 | $444K | Sell |
57,502
-1,958
| -3% | -$15.7K | ﹤0.01% | 4807 |
|
|
2022
Q1 | $559K | Sell |
59,460
-2,044
| -3% | -$18.3K | ﹤0.01% | 4840 |
|
|
2021
Q4 | $427K | Buy |
61,504
+647
| +1% | +$5.44K | ﹤0.01% | 4917 |
|
|
2021
Q3 | $579K | Sell |
60,857
-773
| -1% | -$7.26K | ﹤0.01% | 4716 |
|
|
2021
Q2 | $616K | Sell |
61,630
-9,448
| -13% | -$105K | ﹤0.01% | 4645 |
|
|
2021
Q1 | $831K | Buy |
71,078
+2,017
| +3% | +$33.9K | ﹤0.01% | 4533 |
|
|
2020
Q4 | $2.47M | Buy |
69,061
+400
| +0.6% | +$6.9K | ﹤0.01% | 3973 |
|
|
2020
Q3 | $950K | Sell |
68,661
-433
| -0.6% | -$6.47K | ﹤0.01% | 4128 |
|
|
2020
Q2 | $1.14M | Buy |
69,094
+9,562
| +16% | +$114K | ﹤0.01% | 4013 |
|
|
2020
Q1 | $506K | Sell |
59,532
-203
| -0.3% | -$2.84K | ﹤0.01% | 4049 |
|
|
2019
Q4 | $1.36M | Sell |
59,735
-52
| -0.1% | -$742 | ﹤0.01% | 3906 |
|
|
2019
Q3 | $856K | Buy |
59,787
+283
| +0.5% | +$4.15K | ﹤0.01% | 4037 |
|
|
2019
Q2 | $793K | Sell |
59,504
-142,208
| -71% | -$2.15M | ﹤0.01% | 4080 |
|
|
2019
Q1 | $3.5M | Sell |
201,712
-6,191
| -3% | -$92.3K | ﹤0.01% | 3534 |
|
|
2018
Q4 | $2.85M | Sell |
207,903
-42,773
| -17% | -$753K | ﹤0.01% | 3568 |
|
|
2018
Q3 | $5.39M | Sell |
250,676
-2,596
| -1% | -$78.9K | ﹤0.01% | 3488 |
|
|
2018
Q2 | $10.8M | Buy |
253,272
+2,051
| +0.8% | +$93.9K | ﹤0.01% | 3196 |
|
|
2018
Q1 | $16.4M | Sell |
251,221
-5,649
| -2% | -$400K | ﹤0.01% | 2870 |
|
|
2017
Q4 | $18.8M | Buy |
256,870
+45,091
| +21% | +$3.73M | ﹤0.01% | 2819 |
|
|
2017
Q3 | $19.4M | Buy |
211,779
+15,751
| +8% | +$1.21M | ﹤0.01% | 2825 |
|
|
2017
Q2 | $13M | Sell |
196,028
-13,127
| -6% | -$1.63M | ﹤0.01% | 3026 |
|
|
2017
Q1 | $45.4M | Buy |
209,155
+208,877
| +75,136% | +$29.8M | ﹤0.01% | 2283 |
|
|
2016
Q4 | $26K | Sell |
278
-27
| -9% | -$3.04K | ﹤0.01% | 3180 |
|
|
2016
Q3 | $42K | Hold |
305
| – | – | ﹤0.01% | 3050 |
|
|
2016
Q2 | $30K | Buy |
305
+145
| +91% | +$18K | ﹤0.01% | 3139 |
|
|
2016
Q1 | $26K | Sell |
160
-81
| -34% | -$16.4K | ﹤0.01% | 2722 |
|
|
2015
Q4 | $79K | Buy |
241
+194
| +413% | +$63.1K | ﹤0.01% | 1850 |
|
|
2015
Q3 | $15K | Hold |
47
| – | – | ﹤0.01% | 2556 |
|
|
2015
Q2 | $19K | Sell |
47
-5
| -10% | -$2.13K | ﹤0.01% | 2438 |
|
|
2015
Q1 | $26K | Hold |
52
| – | – | ﹤0.01% | 2238 |
|
|
2014
Q4 | $19K | Hold |
52
| – | – | ﹤0.01% | 2403 |
|
|
2014
Q3 | $10K | Hold |
52
| – | – | ﹤0.01% | 2744 |
|
|
2014
Q2 | $13K | Buy |
52
+1
| +2% | +$203 | ﹤0.01% | 2619 |
|
|
2014
Q1 | $13K | Hold |
51
| – | – | ﹤0.01% | 2579 |
|
|
2013
Q4 | $10K | Hold |
51
| – | – | ﹤0.01% | 2728 |
|
|
2013
Q3 | $9K | Hold |
51
| – | – | ﹤0.01% | 2727 |
|
|
2013
Q2 | $9K | Buy |
+51
| New | +$7.22K | ﹤0.01% | 2717 |
|
BlackRock's LUMO Position: Q4 2024 in Review
BlackRock sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 39,825 shares — an estimated $154K sold.
BlackRock first reported a position in LUMO in Q2 2013 and held it in 46 quarters. The position peaked at $45.4M in Q1 2017. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- BlackRock reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- BlackRock sold 39,825 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $154K.
- BlackRock first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 46 quarters.
- BlackRock's Lumos Pharma, Inc. Common Stock position peaked at $45.4M in Q1 2017.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on BlackRock's 13F filing for Q4 2024, filed 7 Feb 2025.